REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system ...

Organoids are an important component of translational research, particularly for evaluating drug toxicity and tissue-specific responses.

San Diego, CA, 27 January, 2026: iXCells Biotechnologies (“iXCells”), a leading provider of human cell-based solutions and ...

Argano, the world's first and largest Global Specialist Consultancy exclusively focused on the design and delivery of High-Performance Business Operations with an AI-forward approach to transformation ...

Heart disease is one of the top killers in the United States and worldwide. With more than 5 millions heart failure cases per year in US, it is alarming that half of those patients cannot survive ...

NouvNeu004: Recently received I-III all-stage IND approval from the NMPA, making it the world's first cell therapy product for Multiple System Atrophy (MSA) and iRegene's third self-developed product ...

Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson's disease, following compelling Phase I clinical data ...

Designation underscores the potential of this chemically induced, off-the-shelf cell therapy to address a high unmet need in ...

SINGAPORE, Dec. 23, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, ...